iBio
iBio is a Texas-based biotechnology company that researches and develops plant-infused therapeutic proteins and vaccines for the treatment of fibrotic diseases.
Business Model:
Revenue: $2.3M
Employees: 51-200
Industries / Tags:
Detailed iBio Information
Geographic Data
Address: 8800 HSC Pkwy
City: Bryan
State: TX
Zip: 77807
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$2M
Raised Total:$12M
Social
Metrics
1,300,110Website Global Rank
24,978Website Monthly Traffic
Twitter Followers
Description
iBio is a Texas-based biotechnology company that researches and develops plant-infused therapeutic proteins and vaccines for the treatment of fibrotic diseases.
Contact Phone:
+19794460027
Contact Email:
iBio went public on 8/21/2008 on the NYSE
Listed Exchange:
NYSE
IPO Date:
8/21/2008
Ticker Symbol:
IBIO
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2021 | RubrYc Therapeutics | Series A | 0 |
| 8/2021 | RubrYc Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 2/2016 | Post-IPO Equity | $2.2M | 11/2010 | Post-IPO Equity | $7.1M | 9/2009 | Post-IPO Equity | $3M | 10/2010 | Post-IPO Equity | $7.1M | 1/2016 | Post-IPO Equity | $2.2M | 12/2022 | Post-IPO Equity | $3.5M | 4/2009 | IPO | - | 4/2009 | IPO | - |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 9/2022 | RubrYc Therapeutics |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
